کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3327684 1590589 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Quantification of the Mutant CALR Allelic Burden by Digital PCR : Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation
ترجمه فارسی عنوان
سنجش کمی بار جهش CALR آللی با روش PCR دیجیتالی: برنامه کاربردی برای ارزیابی بیماری باقیمانده حداقل پس از پیوند مغز استخوان
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی انفورماتیک سلامت
چکیده انگلیسی

With the recent discovery of CALR mutations, >80% of patients with myeloproliferative neoplasms carry a phenotype-driving mutation. For JAK2 V617F, the most frequent mutation in myeloproliferative neoplasms, accurate determination of mutational loads is of interest at diagnosis, for phenotypic and prognostic purposes, and during follow-up for minimal residual disease assessment. We developed a digital PCR technique that allowed the accurate determination of CALR allelic burdens for the main mutations (types 1 and 2). Compared with the commonly used fluorescent PCR product analysis, digital PCR is more precise, reproducible, and accurate. Furthermore, this method reached a very high sensitivity. We detected at least 0.025% CALR mutants. It can thus be used for patient characterization at diagnosis and for minimal residual disease monitoring. When applied to patients with primary myelofibrosis who underwent hematopoietic stem cell transplant, the digital PCR detected low levels of minimal residual disease. After negativation of the mutational load in all patients, the disease reappeared at a low level in one patient, preceding hematologic relapse. In conclusion, digital PCR adapted to type 1 and 2 CALR mutations is an inexpensive, highly precise, and sensitive technique suitable for evaluation of myeloproliferative neoplasm patients during follow-up.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Journal of Molecular Diagnostics - Volume 18, Issue 1, January 2016, Pages 68–74
نویسندگان
, , , , , , , , , , ,